Good morning, everyone, and nice to see you again. We have returned, so to speak, from our week-long holiday, which mostly involved family and household matters, as one might imagine these days. Nonetheless, we are somewhat invigorated and hope you feel the same after the weekend respite. Of course, those familiar weekday routines have returned. To cope, yes, we are brewing a cup or three of stimulation. Maple bourbon is the choice for now. Please feel free to join us. Meanwhile, here is the latest menu of interesting items to help you along. Hope your day goes reasonably well and, as always, do stay in touch. …
Moderna (MRNA) received an additional $472 million from the U.S. Biomedical Advanced Research and Development Authority to support development of its Covid-19 vaccine, Reuters notes. The additional funding will support late-stage clinical development including an expanded Phase 3 study that is now under way. In April, Moderna had received $483 million from BARDA, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health.
About the Author Reprints
From the LiveMint item – may I observe that it does seem the Indian authorities are more realistic than at least some in the US Congress? – ““We understand that the APIs (active pharmaceutical ingredients) cannot be 100% produced domestically. Companies will have to import some raw materials. So, we will allow them a 30% import limit under the scheme,” {They understand there is no magic solution.)